Day: June 10, 2022

Data from an eight-patient, open-label study demonstrate improvements across multiple biomarkers of mitochondrial function, inflammation, cerebral blood flow, and functional connectivity CY6463 was well tolerated, with no reports of serious adverse events (SAEs) or treatment discontinuation due to adverse events (AEs); oral, once-daily administration provided expected CNS exposure Data support further development of CY6463 in CNS diseases with mitochondrial dysfunction CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function, today announced positive topline data in its signal-seeking clinical study of CY6463, for the potential treatment of Mitochondrial Encephalomyopathy, Lactic...

— NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA’s Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 — — New Phase 2 Study Announced to Evaluate Nirogacestat in Patients with Ovarian Granulosa Cell Tumors — — Eight Clinical Collaborations Evaluating Nirogacestat as a Cornerstone of BCMA Combination Therapy Ongoing; Nirogacestat in Combination with Low Dose of GSK’s BLENREP Being Evaluated in Phase 2 Trial and Advanced into Additional Sub-Studies with Standard of Care Agents — — Mirdametinib Being Evaluated in Monotherapy and Combination Studies in Rare Oncology Indications and Biomarker-Defined Solid Tumors — — BGB-3245 Monotherapy to Advance into Cohort Expansion Studies — — Well Capitalized to Execute Across...

The five-round series has a US $250,000 prize fund at stake and more flexible regulations for pro driversLe Mans Virtual Series 2022/2023 Calendar Photo 1MIAMI, June 10, 2022 (GLOBE NEWSWIRE) — Le Mans Virtual Series, a joint venture between Motorsport Games Inc. (NASDAQ: MSGM) and the Automobile Club de l’Ouest (ACO), returns this September with more of the elite, endurance esports competition, which has attracted world motor racing champions, captured global attention and received plaudits from teams, drivers and fans alike. The announcement was made today at the official ACO annual press conference ahead of the 90th running of the 24 Hours of Le Mans. Last year’s successful Le Mans Virtual Series culminated in a thrilling 24 Hours of Le Mans Virtual in January 2022. Multiple major motorsport manufacturers and their drivers...

BARDA has ordered 500,000 doses of liquid-frozen JYNNEOS® to be manufactured from existing bulk vaccine for delivery in 2022 Order brings the total U.S. inventory of liquid-frozen JYNNEOS to nearly 2 million doses Company upgrades financial guidance for 2022COPENHAGEN, Denmark, June 10, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 500,000 doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox, for delivery in 2022. With the previous order from BARDA for 1.4 million doses of liquid-frozen JYNNEOS, awarded in 2020, this order will bring...

Oslo, 10 June 2022: Yara Deputy Board member Per Harald Eriksen sold 250 shares on Monday 16 May 2022 at a price of NOK 464.50 per share. Following this sale Per Harald Eriksen owns 0 Yara shares. The share sale is considered as PDMR trades under the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and is subject to the disclosure requirements pursuant to MAR article 19. Details of the transaction can be found in the appendix. Silje NygaardInvestor RelationsMobile: +47 957 04 843E-mail: silje.nygaard@yara.comAbout Yara Yara grows knowledge to responsibly feed the world and protect the planet. Supporting our vision of a world without hunger and a planet respected, we pursue a strategy of sustainable value growth, promoting climate-friendly crop nutrition and zero-emission energy solutions. Yara’s ambition is focused on growing a nature...

AS Trigon Property Development (registry code: 10106774, trading code TPD1T, ISIN code EE3100003443; hereinafter the “Company”) will fix the list of shareholders for dividend payment in accordance with the resolutions of the general meeting of shareholders held on 1 June 2022, regarding which information can be found in the company announcment from 1 June 2022) at the end of the working day of the Nasdaq CSD Estonian settlement system on 16 June 2022. In relation to the above, the ex-date for the change of the rights related with the shares of the Company is 15 June 2022. From that date onwards, the person acquiring the shares is not entitled to receive dividends for the financial year 2021. AS Trigon Property Development will pay dividend 0.13 Euros per share on 22 June 2022. Rando TomingasAS Trigon Property DevelopmentMember of the management...

Press release – Paris, June 10th, 2022 SMCP Combined Shareholders’ Meeting of June 9th, 2022 The Annual General Meeting of SMCP shareholders was held in Paris on June 9, 2022, chaired by Mr. Christophe Cuvillier, Chairman of the Board of Directors. 63.98% of SMCP’s share capital participated in this General Meeting. The results of the votes on the resolutions are presented in the appendix to this press release. In particular, the General Meeting approved the annual financial statements and consolidated financial statements for the year ended December 31, 2021 and ratified the co-optation of Ms. Isabelle Guichot, Chief Executive Officer of SMCP, as a director. The presentation and the webcast will be also available on SMCP’s website. ABOUT SMCP SMCP is a global leader in the accessible luxury market with four unique Parisian...